Virpax Pharmaceuticals (VRPX) Stock Forecast, Price Target & Predictions
VRPX Stock Forecast
Virpax Pharmaceuticals stock forecast is as follows: an average price target of $3.00 (represents a 263.64% upside from VRPX’s last price of $0.82) and
VRPX Price Target
Virpax Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 19, 2024 | Naz Rahman | Maxim Group | $3.00 | $1.70 | 76.47% | 263.64% |
The latest Virpax Pharmaceuticals stock forecast, released on Jul 19, 2024 by Naz Rahman from Maxim Group, set a price target of $3.00, which represents a 76.47% increase from the stock price at the time of the forecast ($1.70), and a 263.64% increase from VRPX last price ($0.82).
Virpax Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $3.00 | $3.00 |
| Last Closing Price | $0.82 | $0.82 | $0.82 |
| Upside/Downside | -100.00% | 263.64% | 263.64% |
In the current month, the average price target of Virpax Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Virpax Pharmaceuticals's last price of $0.82. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Virpax Pharmaceuticals Financial Forecast
Virpax Pharmaceuticals Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
Virpax Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VRPX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Virpax Pharmaceuticals EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict VRPX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Virpax Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Virpax Pharmaceuticals Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-1.38M | $-1.42M | $-3.02M |
| High Forecast | $-1.38M | $-1.42M | $-3.02M |
| Low Forecast | $-1.38M | $-1.42M | $-3.02M |
| Surprise % | - | - | - |
Virpax Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VRPX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Virpax Pharmaceuticals SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Virpax Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VRPX last annual SG&A of $NaN (undefined).
Virpax Pharmaceuticals EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-0.70 | $-0.72 | $-1.53 |
| High Forecast | $-0.70 | $-0.72 | $-1.53 |
| Low Forecast | $-0.70 | $-0.72 | $-1.53 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Virpax Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VRPX previous annual EPS of $NaN (undefined).
Virpax Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KPRX | Kiora Pharmaceuticals | $3.54 | $120.00 | 3289.83% | Buy |
| BWV | Onconetix | $0.18 | $4.00 | 2122.22% | Buy |
| LGVN | Longeveron | $1.97 | $10.00 | 407.61% | Buy |
| VRPX | Virpax Pharmaceuticals | $0.83 | $3.00 | 261.45% | - |
| PRAX | Praxis Precision Medicines | $54.02 | $145.83 | 169.96% | Buy |
| PALI | Palisade Bio | $3.59 | $1.50 | -58.22% | Buy |
VRPX Forecast FAQ
Will Virpax Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for VRPX stock, the company can go up by 263.64% (from the last price of $0.825 to the average price target of $3), up by 263.64% based on the highest stock price target, and up by 263.64% based on the lowest stock price target.
Can Virpax Pharmaceuticals stock reach $1?
VRPX's average twelve months analyst stock price target of $3 supports the claim that Virpax Pharmaceuticals can reach $1 in the near future.
What are Virpax Pharmaceuticals's analysts' financial forecasts?
VRPX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-5.832M (high $-5.832M, low $-5.832M), average SG&A $0 (high $0, low $0), and average EPS is $-2.95 (high $-2.95, low $-2.95).